Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Gen Virol ; 100(6): 975-984, 2019 06.
Article in English | MEDLINE | ID: mdl-31090533

ABSTRACT

The development of live-attenuated vaccines against Dengue virus (DENV) has been problematic. Dengvaxia, licensed in several countries where DENV is endemic, has shown low efficacy profiles and there are safety concerns prohibiting its administration to children younger than 9 years old, and the live-attenuated tetravalent vaccine (LATV) developed by NIAID has proven too reactogenic during clinical trialing. In this work we examined whether the combination of TV005, a LATV-derived formulation, with Tetra DIIIC, a subunit vaccine candidate based on fusion proteins derived from structural proteins from all four DENV serotypes, can overcome the respective limitations of these two vaccine approaches. Rhesus macaques were first primed with one or two doses of Tetra DIIIC and then boosted with TV005, following the time course of the appearance of virus-binding and neutralizing antibodies, and evaluating protection by means of a challenge experiment with wild-type viruses. Although the two evaluated prime-boost regimes were equivalent to a single administration of TV005 in terms of the development of virus-binding and neutralizing antibodies as well as the protection against viral challenge, both regimes reduced vaccine viremia to undetectable levels. Thus, the combination of Tetra DIIIC with TV005 offers a potential solution to the reactogenicity problems, which have beset the development of the latter vaccine candidate.


Subject(s)
Dengue Virus/immunology , Dengue/immunology , Recombinant Fusion Proteins/immunology , Vaccines, Attenuated/immunology , Animals , Antibodies, Neutralizing/immunology , Cell Line , Chlorocebus aethiops , Dengue/virology , Female , Immunization/methods , Immunization, Secondary/methods , Macaca mulatta , Male , Vero Cells
2.
Arch Virol ; 162(8): 2247-2256, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28393307

ABSTRACT

Tetra DIIIC is a subunit vaccine candidate based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. This vaccine preparation contains the DIIIC proteins aggregated with a specific immunostimulatory oligodeoxynucleotide (ODN 39M). Tetra DIIIC has already been shown to be immunogenic and protective in mice and monkeys. In this study, we evaluated the immunogenicity in mice of several formulations of Tetra DIIIC containing different amounts of the recombinant proteins. The Tetra DIIIC formulation induced a humoral immune response against the four DENV serotypes, even at the lowest dose assayed. In contrast, the highest level of cell-mediated immunity, measured as frequency of IFNγ-producing cells, was detected in animals immunized with the lowest dose. The protective capacity of the tetravalent formulations was assessed using the mouse model of dengue virus encephalitis. Upon challenge, vaccinated mice showed significantly reduced virus replication in all tested groups. This study provides new information about the functionality of Tetra DIIIC as a vaccine candidate and also supports the crucial role of cell-mediated immunity in protection against dengue virus.


Subject(s)
Antibodies, Viral/blood , Capsid Proteins/immunology , Dengue Vaccines/immunology , Dengue/prevention & control , Immunity, Humoral , Animals , Antibodies, Neutralizing/blood , Brain/virology , Capsid Proteins/genetics , Chlorocebus aethiops , Dengue Virus , Disease Models, Animal , Dose-Response Relationship, Immunologic , Female , Immunity, Cellular , Mice , Mice, Inbred BALB C , Recombinant Proteins/immunology , Vaccines, Subunit/immunology , Vero Cells , Viremia
SELECTION OF CITATIONS
SEARCH DETAIL
...